Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom
By Manya Saini and Niket Nishant Oct 8 (Reuters) - Nvidia-backed Iambic Therapeutics, which uses AI to develop drugs, is aiming to raise up to $159.4 million in its US IPO, as the biotech sector emerges as a bright spot in an otherwise lackluster market.